Medtronic Hit With Shareholder Suit Over Infuse Studies

Law360, New York (June 28, 2013, 6:01 PM EDT) -- Medical device maker Medtronic Inc. helped researchers downplay the risks and side effects of its Infuse bone graft product, causing its stock price to fall when the scheme was revealed, a Minnesota securities class action filed Thursday alleges.

Minneapolis-based Medtronic allegedly worked with some researchers to hide Infuse's risks and then didn't disclose that when those risks were revealed surgeons would stop using it as much, inflating and then bringing the company's stock price down from 2010 to 2011, according to a complaint filed by the...
To view the full article, register now.